Patients with late-relapse metastatic renal cell carcinoma (RCC) treated with targeted therapy achieved prolonged survival that was similar to historical controls, according to a retrospective analysis involving 24 individuals. However, metastases were seen in uncommon sites. Median age of participants was 72 with metastatic RCC that was diagnosed >5 years after nephrectomy. 71% had favorable and 25% unfavorable risk. They received targeted therapy with pazopanib (46%), sorafenib (25%), sunitinib (17%), or cytokine (13%) at a single center. Among the results:

• Overall, median overall survival was ~5 years.
• 3-year overall survival rate was 72%.
• There were no treatment failure differences between therapies.
• Patients spent a median of ~20 months on first-line therapy.
• ~Two-thirds received second-line treatment.
• Metastases were seen in historically uncommon areas (pancreas, adrenal glands, and soft tissue).